In 2023, Renin-Angiotensin System medicine sales in Germany were at 1.98 billion Euros. The forecasted sales show a steady growth from 2024 to 2028, with values increasing year-on-year by approximately 1.49% each year. The Compound Annual Growth Rate (CAGR) over the five-year period from 2024 to 2028 is projected at 1.49%.

Future trends to watch for include:

Further advancements in cardiovascular treatment options could impact sales trajectories.
Regulatory changes in the German healthcare system affecting drug pricing and reimbursement policies.
Innovations in digital health and telemedicine influencing patient treatment choices and adherence.